FOLD News and Press, Amicus Therapeutics Inc. From 02/04/19

"A cynic is a man who, when he smells flowers, looks around for a coffin." - H.L. Mencken Stocks ended January on a high note with the major indices up just under one and half percent last week. It was the best start to a New Year since 1987 for investors after a dismal fourth quarter. T...

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more ...

Amicus Therapeutics (NASDAQ: FOLD ) initiated with Overweight rating and $20 (76% upside) price target at Cantor Fitzgerald. Shares up  2%  premarket. More news on: Amicus Therapeutics, Inc., Intercept Pharmaceuticals, Allergan plc, Healthcare stocks news, Stocks on the move, , ...

NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. 15. The Dow Jones Industrial Average climbed 0.75 percent to settle at 24,737.20, while ...

Amicus Therapeutics ( FOLD -4.8% ) slips on almost double normal volume in reaction to its privately negotiated agreements to exchange a portion of its 3% Convertible Senior Notes due 2023 for stock. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...

CRANBURY, N.J., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that four oral presentations and eight posters highlighting...

Amicus Therapeutics ( FOLD +0.7% ) provides preliminary Galafold revenue for FY 2018 and introduced FY 2019 strategic outlook and financial guidance. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Read more ...

Full-Year 2018 Galafold Revenue of ~$91M Exceeds $80M-$90M Guidance 2019 Galafold Revenue Expected to Nearly Double – with Guidance of $160M-$180M Pompe Phase 3 PROPEL Study Expected to Complete Enrollment and Additional Phase 2 Pompe Data in 2019 Additional 2-Y...

Amicus Therapeutics, Inc. (FOLD) Q3 2018 Earnings Conference Call November 05, 2018 08:30 AM ET Executives Sara Pellegrino - IR John Crowley - Chairman and CEO Bradley Campbell - President and COO Chip Baird - CFO Hung Do - Chief Science Officer Jeff Castelli - Chief Portfo...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2018 Q3 earnings Read more ...